CY1120618T1 - Αναλογα αγωνιστων υποδοχεων mu οπιοειδων των ενδομορφινων - Google Patents
Αναλογα αγωνιστων υποδοχεων mu οπιοειδων των ενδομορφινωνInfo
- Publication number
- CY1120618T1 CY1120618T1 CY171100700T CY171100700T CY1120618T1 CY 1120618 T1 CY1120618 T1 CY 1120618T1 CY 171100700 T CY171100700 T CY 171100700T CY 171100700 T CY171100700 T CY 171100700T CY 1120618 T1 CY1120618 T1 CY 1120618T1
- Authority
- CY
- Cyprus
- Prior art keywords
- analogues
- amino acid
- opiodic
- endomorphin
- competitive
- Prior art date
Links
- 230000002860 competitive effect Effects 0.000 title 1
- 208000002193 Pain Diseases 0.000 abstract 2
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 108010069514 Cyclic Peptides Proteins 0.000 abstract 1
- 102000001189 Cyclic Peptides Human genes 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 208000005298 acute pain Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 125000004122 cyclic group Chemical group 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002349 favourable effect Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 231100001274 therapeutic index Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
- C07K5/126—Tetrapeptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36303910P | 2010-07-09 | 2010-07-09 | |
| PCT/US2011/043306 WO2012006497A2 (en) | 2010-07-09 | 2011-07-08 | Mu opioid receptor agonist analogs of the endomorphins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120618T1 true CY1120618T1 (el) | 2019-12-11 |
Family
ID=45441820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY171100700T CY1120618T1 (el) | 2010-07-09 | 2017-07-03 | Αναλογα αγωνιστων υποδοχεων mu οπιοειδων των ενδομορφινων |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US8716436B2 (enExample) |
| EP (2) | EP2590992B1 (enExample) |
| JP (2) | JP6039553B2 (enExample) |
| CA (1) | CA2810170C (enExample) |
| CY (1) | CY1120618T1 (enExample) |
| ES (1) | ES2632787T3 (enExample) |
| HR (1) | HRP20171119T1 (enExample) |
| HU (1) | HUE033875T2 (enExample) |
| PL (1) | PL2590992T3 (enExample) |
| PT (1) | PT2590992T (enExample) |
| RS (1) | RS56129B1 (enExample) |
| SI (1) | SI2590992T1 (enExample) |
| WO (1) | WO2012006497A2 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110065648A1 (en) * | 2009-09-15 | 2011-03-17 | Maione Theodore E | Advantageous mu-opiate receptor peptide compounds |
| US20160176930A1 (en) | 2010-07-09 | 2016-06-23 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| WO2014137496A1 (en) * | 2013-03-08 | 2014-09-12 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| US20130178427A1 (en) * | 2010-07-09 | 2013-07-11 | The Administrators Of The Tulane Educational Fund | Mu opioid receptor agonist analogs of the endomorphins |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| EP3681900A4 (en) | 2017-09-11 | 2021-09-08 | Protagonist Therapeutics, Inc. | OPIOID AGONIST PEPTIDES AND THEIR USES |
| CN111511757A (zh) | 2017-11-17 | 2020-08-07 | 细胞凝胶制药有限责任公司 | μ阿片受体的聚合物激动剂 |
| CN111683654A (zh) * | 2017-11-30 | 2020-09-18 | 细胞凝胶制药有限责任公司 | 新型镇痛药物制剂及其用途 |
| US11578100B2 (en) | 2018-03-28 | 2023-02-14 | Florida Atlantic University Research Corporation | Cyclic peptides, cyclic peptide conjugates and methods of use thereof |
| RU2687740C1 (ru) * | 2018-11-26 | 2019-05-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Применение пептида Gly-His-Lys-Pro-Gly-Pro для достижения анальгетического эффекта при боли, вызванной температурным раздражением |
| EP3962928A4 (en) * | 2019-05-03 | 2023-05-17 | The Administrators of The Tulane Educational Fund | METHODS OF TREATMENT OF OPIOID USE DISEASE |
| WO2023235232A2 (en) * | 2022-05-31 | 2023-12-07 | The Administrators Of The Tulane Educational Fund | Glycosylated cyclic endomorphin analogs |
| CN116120402B (zh) * | 2022-11-04 | 2024-03-15 | 深圳市维琪科技股份有限公司 | 一种环肽及其组合物和用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9203496D0 (sv) * | 1992-11-20 | 1992-11-20 | Kabi Pharmacia Ab | New oligopeptides |
| US5885958A (en) | 1997-03-25 | 1999-03-23 | Administrators Of The Tulane Educational Fund | Mu-opiate receptor peptides |
| US6759520B1 (en) * | 1999-10-28 | 2004-07-06 | The New England Medical Center Hospitals, Inc. | Chimeric analgesic peptides |
| JP2006525942A (ja) | 2002-12-23 | 2006-11-16 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | トロンビン受容体アンタゴニストとしての新規なヘテロアリールペプチド模倣物 |
| US7399762B2 (en) * | 2005-04-25 | 2008-07-15 | Research Triangle Institute | Opioid receptor agonist compounds and their use in treatment of pain |
| US8809278B2 (en) * | 2008-07-11 | 2014-08-19 | University Of Kansas | Cyclic tetrapeptides |
-
2011
- 2011-07-08 EP EP11804387.6A patent/EP2590992B1/en not_active Not-in-force
- 2011-07-08 HR HRP20171119TT patent/HRP20171119T1/hr unknown
- 2011-07-08 PT PT118043876T patent/PT2590992T/pt unknown
- 2011-07-08 CA CA2810170A patent/CA2810170C/en not_active Expired - Fee Related
- 2011-07-08 HU HUE11804387A patent/HUE033875T2/en unknown
- 2011-07-08 JP JP2013519718A patent/JP6039553B2/ja not_active Expired - Fee Related
- 2011-07-08 SI SI201131226T patent/SI2590992T1/sl unknown
- 2011-07-08 PL PL11804387T patent/PL2590992T3/pl unknown
- 2011-07-08 ES ES11804387.6T patent/ES2632787T3/es active Active
- 2011-07-08 RS RS20170643A patent/RS56129B1/sr unknown
- 2011-07-08 WO PCT/US2011/043306 patent/WO2012006497A2/en not_active Ceased
- 2011-07-08 EP EP17167969.9A patent/EP3246333B1/en not_active Not-in-force
-
2012
- 2012-05-22 US US13/477,423 patent/US8716436B2/en not_active Expired - Fee Related
-
2014
- 2014-05-02 US US14/268,057 patent/US20150315238A1/en not_active Abandoned
-
2016
- 2016-01-21 JP JP2016010055A patent/JP6279626B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-03 CY CY171100700T patent/CY1120618T1/el unknown
- 2017-09-14 US US15/704,730 patent/US20180222940A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2632787T3 (es) | 2017-09-15 |
| EP2590992B1 (en) | 2017-04-26 |
| US20180222940A1 (en) | 2018-08-09 |
| HK1246811A1 (en) | 2018-09-14 |
| CA2810170C (en) | 2022-01-25 |
| EP3246333B1 (en) | 2020-10-07 |
| AU2011274522A1 (en) | 2013-02-07 |
| US8716436B2 (en) | 2014-05-06 |
| PL2590992T3 (pl) | 2017-09-29 |
| HUE033875T2 (en) | 2018-01-29 |
| EP2590992A4 (en) | 2013-12-18 |
| JP2016084357A (ja) | 2016-05-19 |
| JP2013533890A (ja) | 2013-08-29 |
| AU2011274522B2 (en) | 2016-03-31 |
| WO2012006497A3 (en) | 2012-05-24 |
| US20150315238A1 (en) | 2015-11-05 |
| HRP20171119T1 (hr) | 2017-10-06 |
| PT2590992T (pt) | 2017-07-26 |
| RS56129B1 (sr) | 2017-10-31 |
| EP3246333A1 (en) | 2017-11-22 |
| JP6279626B2 (ja) | 2018-02-14 |
| SI2590992T1 (sl) | 2017-11-30 |
| CA2810170A1 (en) | 2012-01-12 |
| JP6039553B2 (ja) | 2016-12-07 |
| AU2011274522A8 (en) | 2016-04-14 |
| EP2590992A2 (en) | 2013-05-15 |
| US20120322740A1 (en) | 2012-12-20 |
| WO2012006497A2 (en) | 2012-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2590992A4 (en) | MU OPIOID RECEPTOR AGONIST ANALOGUE OF ENDOMORPHINES | |
| PE20121393A1 (es) | Analogo peptidico de oxintomodulina | |
| JP2022542291A5 (enExample) | ||
| ES2512141T3 (es) | Análogo peptídico de oxintomodulina | |
| CY1120399T1 (el) | Ενδορινικες φαρμακευτικες δοσολογικες μορφες οι οποιες περιλαμβανουν ναλοξονη | |
| PE20090108A1 (es) | Coagonistas del receptor de glucagon/glp-1 | |
| CO6241137A2 (es) | Antagonistas ciclicos de peptido cxcr4 | |
| JP2011511753A5 (enExample) | ||
| CY1123014T1 (el) | Αναστολη των πεπτιδιων που προερχονται απο τον υποδοχεα ενεργοποιησης που εκφραζεται σε μυελοειδη κυτταρα-1 (trem-1) και το μεταγραφο τυπου trem 1 (tlt-1) και χρησεις αυτων | |
| JP2013511554A5 (enExample) | ||
| EP2651420A4 (en) | PEPTIDE-BASED IN VIVO SIRNA RELEASE SYSTEM | |
| RU2017105115A (ru) | Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника | |
| CO6331292A2 (es) | Compuestos de insulina lispro pegilada | |
| PH12014501642A1 (en) | Peptide vaccines for cancers expressing tumor-associated antigens | |
| PE20142332A1 (es) | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas | |
| WO2011156453A3 (en) | Therapeutic peptides | |
| NZ601175A (en) | Hla-a*1101-restricted wt1 peptide and pharmaceutical composition comprising the same | |
| SG194717A1 (en) | High-affinity, dimeric inhibitors of psd-95 as efficient neuroprotectants againstischemic brain damage and for treatment of pain | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| RU2013120135A (ru) | Глюкозозависимые инсулинотропные пептидные аналоги | |
| RU2016130448A (ru) | Пептидные дендримеры, содержащие фибриноген-связывающие пептиды | |
| RU2015110114A (ru) | Ангиотензин в лечении состояний головного мозга | |
| JP2016516734A5 (enExample) | ||
| CY1114619T1 (el) | Συνθετικα αναλογα πεπτιδιων νευρικης αναγεννησης | |
| EA201500061A1 (ru) | Фармацевтическая композиция для терапии легочной формы высотной болезни, вызванной кислородным голоданием и пониженным атмосферным давлением |